Hypersensitivity Reactions to Biologic Agents

Immunology and Allergy Clinics of North America

Volumn 34, Issue 3, 2014, Pages 615-632

  Vultaggio, Alessandra ^a   Castells, Mariana C ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antidrug antibodies; Biologic agents; Drug allergy; Hypersensitivity reactions; Immunogenicity

Indexed keywords

ABCIXIMAB; ADALIMUMAB; BIOLOGICAL PRODUCT; CETUXIMAB; CORTICOSTEROID; ETANERCEPT; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E; INFLIXIMAB; NATALIZUMAB; OMALIZUMAB; RITUXIMAB; STEROID; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; BIOLOGICAL FACTOR;

ABDOMINAL PAIN; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY DETECTION; ARTHRALGIA; B LYMPHOCYTE; BRONCHOSPASM; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; CYTOKINE RELEASE; DENDRITIC CELL; DESENSITIZATION; DISEASE SEVERITY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEVER; FLUSHING; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFUSION RELATED REACTION; INJECTION SITE REACTION; INTRACUTANEOUS TEST; LIFE THREAT; MAST CELL; MELENA; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; OXYGEN SUPPLY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RESPIRATORY DISTRESS; REVIEW; RHINITIS; SKIN TEST; STEVENS JOHNSON SYNDROME; SYMPTOMATOLOGY; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VOMITING; DISEASE MANAGEMENT; HYPERSENSITIVITY;

BIOLOGICAL FACTORS; DESENSITIZATION, IMMUNOLOGIC; DISEASE MANAGEMENT; HUMANS; HYPERSENSITIVITY;

EID: 84904054072     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2014.04.008     Document Type: Review

References (73)

1. Kotsovilis S., Andreakos E. Therapeutic human monoclonal antibodies in inflammatory diseases. Methods Mol Biol 2014, 1060:37-59.
2. Li G.N., Wang S.P., Xue X., et al. Monoclonal antibody-related drug for cancer therapy. Drug Discov Ther 2013, 7(5):178-184.
3. Buss N.A., Henderson S.J., McFarlane M., et al. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 2012, 12(5):615-622.
4. Borchers A.T., Leibushor N., Cheema G.S., et al. Immune mediated adverse effects of biological used in the treatment of rheumatic diseases. JAutoimmun 2011, 37:273-288.
5. Vultaggio A, Nencini F, Pratesi S, etal. Manifestations of anti-drug antibodies response: hypersensitivity and infusion reactions. J Int Cyt Res, in press.
6. Pichler W.J. Adverse side-effects to biologicals. Allergy 2006, 61(8):912-920.
7. Maggi E., Vultaggio A., Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011, 7:55-63.
8. Lenz H.J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007, 12:601-609.
9. Matucci A., Pratesi S., Petroni G., et al. Allergological invitro and invivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy 2013, 43(6):659-664.
10. Scherer K., Spoerl D., Bircher A.J. Adverse drug reactions to biologics. JDtsch Dermatol Ges 2010, 8(6):411-426.
11. Proctor L., Renzulli B., Warren S., et al. Monoclonal antibody-stimulated serum sickness. Transfusion 2004, 44:955.
12. Gamarra R.M., McGraw S.D., Drelichman V.S., et al. Serum sickness-like reactions in patients receiving intravenous infliximab. JEmerg Med 2006, 30(1):41-44.
13. D'Arcy C.A., Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001, 44:1717-1718.
14. Pilette C., Coppens N., Houssiayu F.A., et al. Severe serum sickness-like syndrome after omalizumab therapy for asthma. JAllergy Clin Immunol 2007, 120(4):972-973.
15. Hellwing K., Schimrigk S., Fischer M., et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol 2008, 65(5):656-658.
16. Cuker A., Coles A.J., Sullivan H., et al. Adistinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood 2011, 118(24):6299-6305.
17. Berzuini A., Montanelli F., Prati D. Hemolytic anemia after eculizumab in paroxysmal nocturnal hemoglobinuria. NEngl J Med 2010, 363(10):993-994.
18. Calogiuri G., Ventura M.T., Mason L., et al. Hypersensitivity reactons to last generation chimeric, humanized and human recombinant monoclonal antibodies for therapeutic use. Curr Pharm Des 2008, 14:2883-2891.
19. Bremmer M., Deng A., Gaspari A. Amechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease. Part 1. Dermatitis 2009, 20:182-192.
20. Vergara G., Silvestre J.F., Betlloch I., et al. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 2002, 138:1258-1259.
21. Bremmer M., Deng A., Gaspari A. Amechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease. Part 2. Dermatitis 2009, 20:243-256.
22. Lin W.L., Lin W.C., Yang J.Y., et al. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. JClin Oncol 2008, 26:2779-2780.
23. Sfikakis P.P., IIiopoulos A., Elezoglou A., et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reactrion. Arthritis Rheum 2005, 52(8):2513-2518.
24. Lenz H.J. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology (Williston Park) 2006, 20:5-13.
25. Murdaca G., Spanò F., Puppo F. Selective TNF-a inhibitor induced-injection site reactions. Expert Opin Drug Saf 2013, 12(2):187-193.
26. Vultaggio A., Maggi E., Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol 2011, 11(3):262-268.
27. Wing M. Monoclonal antibody first dose cytokine release syndrome - mechanisms and prediction. JImmunotoxicology 2008, 5:11-15.
28. Brennan F.R., Morton Dill L., Spindeldreher S., et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2010, 2(3):233-255.
29. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. NEngl J Med 2003, 348(7):601-608.
30. Svenson M., Geborek P., Saxne T., et al. Monitoring patients treated with anti-TNF-α biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007, 46:1828-1834.
31. Finkelman F.D. Anaphylaxis: lessons from mouse model. JAllergy Clin Immunol 2007, 120:506-515.
32. Georgitis J.W., Browning M.C., Steiner D., et al. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. Ann Allergy 1991, 66:343-347.
33. Stubenrauch K., Wessels U., Birnboeck H., et al. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an anti-drug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 2010, 32:1597-1609.
34. Bavbek S., Aydin O., Ataman S., et al. Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization. Allergy 2011, 66(9):1256-1257.
35. Munoz-Cano R., Carnes J., Sanchez-Lopez J., et al. Biological agents: new drugs, old problems. JAllergy Clin Immunol 2010, 126:394-395.
36. Vultaggio A., Matucci A., Nencini F., et al. Anti-infliximab IgE and non IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010, 65:657-661.
37. Vultaggio A., Matucci A., Nencini F., et al. Drug-specific th2 cells and ige antibodies in a patient with anaphylaxis to rituximab. Int Arch Allergy Immunol 2012, 359:321-326.
38. Brennan P.J., Bouza T.R., Hsu F.I., et al. Hypersensitivity reactions to mAbs:105 desensitizations in 23 patients, from evalutaion to treatment. JAllergy Clin Immunol 2009, 124:1259-1266.
39. Vultaggio A., Matucci A., Parronchi P., et al. Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience. Int J Immunopathol Pharmacol 2008, 21:367-374.
40. Lee T.W., Singh R., Fedorak R.N. Aone-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. Aliment Pharmacol Ther 2001, 34:181-187.
41. Chung C.H., Mirakhur B., Chan E., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. NEngl J Med 2008, 358:1109-1117.
42. Price K.S., Hamilton R.G. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007, 28:313-319.
43. Steele R.H., Limaye S., Cleland B., et al. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology (Carlton) 2005, 10:317-320.
44. Torres M.J., Chaves P., Blanca-Lopez N., et al. T-cell involvement in delayed type hypersensitivity reactions to infliximab. JAllergy Clin Immunol 2011, 128(6):1365-1367.
45. Moneret-Vautrin D.A., Morisset M., Vignaud J.M., et al. Tcell mediated allergy to abciximab. Allergy 2002, 57:269-270.
46. Winfield H., Lain E., Horn T., et al. Eosinophilic cellulitis like reaction to subcutaneous etanercept injection. Arch Dermatol 2006, 142(2):218-220.
47. Werth V.P., Levinsion A.I. Etanercept-induced injection site reactions, mechanistic insights from clinical fidings and immunohistochemistry. Arch Dermatol 2001, 137:953-955.
48. Benucci M., Mandredi M., Saviola G., et al. Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. Clin Exp Rheumatol 2009, 27(2):333-336.
49. Maneiro J.R., Salgado E., Gomez-Reino J.J. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med 2013, 173(15):1416-1428.
50. Lee S., Ballow M. Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune disease. JAllergy Clin Immunol 2010, 125:814-820.
51. Sehn L.H., Donaldson J., Filewich A., et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safetly be delivered in the community setting. Blood 2007, 109:4171-4173.
52. Anderson P.J. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005, 34(Suppl 1):19-22.
53. Du Pan S.M., Dehler S., Ciurea A., Swiss Clinical Quality Management Physicians, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009, 61:560-568.
54. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
55. Lecluse L.L., Piskin G., Mekkes J.R., et al. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 2008, 159:527-536.
56. Murdaca G., Colombo B.M., Cagnati P., et al. Update upon efficacy and safety of TNF-a inhibitors. Expert Opin Drug Saf 2012, 11(1):1-5.
57. Vogel W.H. Infusion reactions: diagnosis, assessment and management. Clin J Oncol Nurs 2010, 14:E10-E21.
58. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., et al. Reccomendations for the design and optimization of immunoassay used in the detection of host antibodies against biotechnology products. JImmunol Methods 2004, 289:1-16.
59. Rispens T., de Vrieze H., de Groot E., et al. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. JImmunol Methods 2012, 375(1-2):93-99.
60. Aarden L., Ruuls S.R., Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008, 20(4):431-435.
61. Serarslan G., Okuyucu E., Melek I., et al. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis. Mult Scler 2008, 14:259-261.
62. Poreaux C., Waton J., Cuny J.F., et al. Evaluation d'une pratique de prise en charge des taxidermies dues a l'interferon: a propos de 15 cas. Ann Dermatol Venereol 2009, 136:s317-s318.
63. Castells M.C., Tennant N.M., Sloane D.E., et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. JAllergy Clin Immunol 2008, 122(3):574-580.
64. Puchner T.C., Kugathasan S., Kelly K.J., et al. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001, 7(1):34-37.
65. Cheifetz A., Smedley M., Martin S., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003, 98(6):1315-1324.
66. Duburque C., Lelong J., Iacob R., et al. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther 2006, 24(5):851-858.
67. Rodriguez-Jimenez B., Dominguez-Ortega J., González-Herrada C., et al. Successful adalimumab desensitization after generalized urticaria and rhinitis. JInvestig Allergol Clin Immunol 2009, 19(3):246-247.
68. Bavbek S., Ataman S., Bankova L., et al. Injection site reaction to adalimumab: positive skin test and successful rapid desensitization. Allergol Immunopathol 2013, 41(3):204-206.
69. Saif M.W., Syrigos K.I., Hotchkiss S., et al. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 2009, 65(1):107-112.
70. Jerath M.R., Kwan M., Kannarkat M., et al. Adesensitization protocol for the mAb cetuximab. JAllergy Clin Immunol 2009, 123:260-262.
71. Cook-Bruns N. Retrospective analysis of the safety of herceptin immunotherapy in metastatic breast cancer. Oncology 2001, 61(Suppl 2):S58-S66.
72. Melamad J., Stahlman J. Rapid desensitization and rush immunotherapy to trastuzumab. JAllergy Clin Immunol 2002, 110:813-814.
73. Jacquener S., Moneret-Vautrin D.A., Bihain B. Mammalian meat-induced anhaphylaxis: clinical relevance of anti-galactose-a-1,3-galactose IgE confirmed by means of skin tests to cetuximab. JAllergy Clin Immunol 2009, 124:603-605.